Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression

Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial

Brief Summary: Purpose of this study is to evaluate efficacy of hydroxychloroquine (HCQ) in reducing progression of Corona Virus Disease 2019 (COVID - 19) and achieving viral clearance.

Condition or disease :I COVID-19 ntervention/treatment :Drug: Hydroxychloroquine Sulfate Phase: Phase III

This study explores efficacy of HCQ (400mg BD on D0 and 200mg BD D1-D5) in reducing progression of Mild Covid-19 patients and decreasing viral load.

Participants of study will be randomized 2:1 to receive either Active drug or standard of care (SOC) treatment respectively. We aim to demonstrate reduced COVID-19 progression and early viral clearance in individuals on HCQ therapy.

Inclusion Criteria:

• Mild Corona virus disease (COVID-19)
• PCR confirmed infection
• Hospital admitted patients

Exclusion Criteria:

• Moderate, severe and critical COVID-19
• day 0 CRP greater than 6mg/dl, ALC < 1000 or evidence of infiltrates on X-ray chest
• comorbidity with life expectancy less than 6 months
• Contraindications to HCQ therapy